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Diffuse large B-cell lymphoma (DLBCL) is the most common form
of lymphoma in adults. The disease exhibits a striking heteroge-
neity in gene expression proﬁles and clinical outcomes, but its
genetic causes remain to be fully deﬁned. Through whole genome
and exome sequencing, we characterized the genetic diversity of
DLBCL. In all, we sequenced 73 DLBCL primary tumors (34 with
matched normal DNA). Separately, we sequenced the exomes of
21 DLBCL cell lines. We identiﬁed 322 DLBCL cancer genes that
were recurrently mutated in primary DLBCLs. We identiﬁed recur-
rent mutations implicating a number of known and not previously
identiﬁed genes and pathways in DLBCL including those related to
chromatin modiﬁcation (ARID1A and MEF2B), NF-κB (CARD11 and
TNFAIP3), PI3 kinase (PIK3CD, PIK3R1, and MTOR), B-cell lineage
(IRF8, POU2F2, and GNA13), and WNT signaling (WIF1). We also
experimentally validated a mutation in PIK3CD, a gene not pre-
viously implicated in lymphomas. The patterns of mutation dem-
onstrated a classic long tail distribution with substantial variation
of mutated genes from patient to patient and also between pub-
lished studies. Thus, our study reveals the tremendous genetic
heterogeneity that underlies lymphomas and highlights the need
for personalized medicine approaches to treating these patients.
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Diffuse large B-cell lymphoma (DLBCL) is the most commonform of lymphoma in adults (1). Although nearly half the
Results
Sequencing of a Lymphoma Genome Uncovers the Spectrum of
Somatic Variation in DLBCL. Lymphoma biopsy tissue and unaf-
fected bone marrow were obtained from the same patient. Using
the Illumina platform, we generated at total of 171 Gb of 100 bp
paired-end sequences from the tumor and matched normal ge-
nomes corresponding to an average per-base sequencing cover-
age of 37-fold and 20-fold, respectively.
We identiﬁed 23,214 somatic sequence alterations occurring
throughout the lymphoma genome, summarized in Fig. 1 A and B
and SI Appendix, Table S1.
Transitions accounted for about 60% of these events (Fig. 1C),
similar to patterns observed in a number of other malignancies
(9–11) and suggest that the majority of these DLBCL mutations
arise from stochastic endogenous processes rather than envi-
ronmental exposures, for example, in the context of tobacco
exposure and lung cancer (6).
Known oncogenes (12) found to be somatically mutated in this
DLBCL patient included ARID1A, SETD2, CARD11, and
PIK3R1. Of these genes, only CARD11 (13) has been previously
experimentally identiﬁed as an oncogene in DLBCL. We also
identiﬁed structural genetic alterations using approaches de-
scribed previously (14, 15). In all, we identiﬁed seven deletions
and three ampliﬁcations. Known oncogenes that were implicated
by these copy number alterations include PTEN (chromosome
10) and CDKN2A (chromosome 9).
Exome Sequencing Deﬁnes the Spectrum of Coding Region Mutations
in DLBCL. To identify recurrently mutated genes in DLBCLs, we
obtained a total of 73 cases of primary human samples. We di-
vided the primary human cases into a discovery set (n = 34) and
a prevalence set (n = 39). For each of the discovery set cases of
primary DLBCLs, we also sequenced paired normal tissue. In
addition, we sequenced the exomes of 21 DLBCL cell lines that
are widely used to model the disease.
Author contributions: J. Zhang, V.G., C.L.L., A.J.J., J.C.B., M.A.L., and S.S.D. designed re-
search; J. Zhang, V.G., C.L.L., K.L.R., P.A.M., C.D., W.C., W.Y.A., G.S., P.L.L., D.A.R., A.S.L.,
L.B.-M., K.P.M., C.F., K.N., A.E., L.I.G., M.C., J.I.G., E.D.H., Q.L., K.W., L.L.S., T.N., J. Zhu, A.C.,
S.L., and S.S.D. performed research; J. Zhang, V.G., A.B., A.F., D.J., M.A.L., D.D., and S.S.D.
analyzed data; and J. Zhang, V.G., C.L.L., and S.S.D. wrote the paper.
The authors declare no conﬂict of interest.
*This Direct Submission article had a prearranged editor.
Data deposition: The data reported in this paper have been deposited in dbGap, http://
www.ncbi.nlm.nih.gov/gap (accession no. phs000573.v1.p1), and the Gene Expression
Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE22898).
1J. Zhang and V.G. contributed equally to this work.
2To whom correspondence should be addressed. E-mail: sandeep.dave@duke.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1205299110/-/DCSupplemental.
patients can be cured with standard regimens, the majority of 
relapsed patients succumb. Thus, there is an urgent need to 
identify the genetic underpinnings of the disease and to identify 
novel treatment strategies. Gene expression proﬁling (2, 3) has 
uncovered distinct molecular signatures for DLBCL subtypes that 
have unique biology and prognoses. High-throughput sequencing 
has provided rich opportunities for the comprehensive identiﬁ-
cation of the genetic causes of cancer (4–6). Whereas exhaustive 
portraits of individual cancer genomes are emerging, the degree 
to which these genomes represent the disease is unclear.
We generated a detailed analysis of a DLBCL genome by se-
quencing a primary human tumor and paired normal tissue 
(Dataset S1). We further characterized the genetic diversity of 
DLBCL by sequencing the exomes of 73 DLBCL primary tumors 
(34 with matched normal DNA) and 21 DLBCL cell lines for 
comparative purposes. This in-depth sequencing identiﬁed 322 
DLBCL cancer genes that were recurrently mutated in DLBCLs. 
We also experimentally validated the effects of genetic alteration 
of PIK3CD, an oncogene that we identiﬁed in DLBCL. Our work 
provides one of the largest genetic portraits yet of human 
DLBCLs and offers insights into the molecular heterogeneity of 
the disease, especially in the context of other recently published 
studies in DLBCL (7, 8).
We empirically explored the power of our study to identify
novel genetic variants by plotting the expected number of new
variants that would be discovered from each additional case of
DLBCL (SI Appendix). We found a progressively smaller number
of unique variants by sequencing each additional sample (Fig.
2C). By n = 25, the number of additional variants contributed by
each additional sample fell to less than 1% of the total (Fig. 2C).
These values corresponded well with a regression model for
exponential increase (R2 = 0.8768, P < 10−6).
However, the vast majority of these variants depicted in Fig.
2C were common variants and present in our normal controls.
The number of rare variants (<1% frequency in the general
population) discovered per additional sample remained rela-
tively constant and increased linearly with each additional case
(Fig. 2D). Similarly, the number of somatic variants identiﬁed
in our discovery set (i.e., variants absent from the corre-
sponding paired normal tissue) also increased linearly with the
addition of each individual pair of tumor-normal sets (Fig. 2E).
The number of individual genes implicated by sequencing
additional samples showed a similar linear increase as a func-
tion of the number of cases. Because cancer arises predomi-
nantly from such somatically acquired rare variants, these
ﬁndings have implications for the number of samples needed
to comprehensively characterize a heterogeneous disease like
DLBCL, as discussed below.
Patterns of Exome Variation and Identiﬁcation of DLBCL Cancer
Genes. We began analysis by aligning the sequencing reads to
the genome and determining the distribution of our mutations:
53.8% of the variants were missense, and nonsense, frameshift,
and synonymous variants comprised 1.1%, 2.4%, and 42.7% of
the total number of variants, respectively (Fig. 2F). These overall
patterns of genetic variation in the DLBCL exomes are quite
similar to what we would expect in the variation of normal exomes
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Fig. 1. Results from sequencing a lymphoma ge-
nome. (A) Circos diagram (36) summarizing the
somatically acquired genetic variants in a DLBCL
genome. The outermost ring depicts the chromo-
some ideogram oriented clockwise, pter-qter. The
next ring indicates copy number alterations in the
DLCBL genome. The next three rings indicate so-
matically acquired mutations in intergenic regions,
potential regulatory regions, and the exome re-
spectively. (B) Pie chart depicts the relative number
of somatically acquired mutations in the DLBCL
genome, which can be classiﬁed by their genomic
location as intergenic, intronic, potential regula-
tory, or transcribed regions (Left). (Right) Break-
down of different mutation types observed in the
transcribed regions. (C) Histogram depicts the mu-
tation proﬁle of DLBCL. The proportion of muta-
tions in each of the six mutational classes is shown.
Transitions represent the majority of the somati-
cally acquired mutations (P < 10−6).
We performed whole-exome sequencing for all of these 
DLBCL and paired normal cases using the Agilent solution–
based system of exon capture, which targets the NCBI Consensus 
CDS database (CCDS) (16). We generated more than 500 Gb of 
mappable sequence data and generated sequence data for 94%
(median) of the targeted bases in each sample. Our average exome 
coverage was 47-fold (median, 42.5-fold) per targeted base (Fig. 
2A). In all, we identiﬁed 121,589 distinct variants in these cases.
Validation of Genetic Variant Identiﬁcation. To verify our methods 
for exome capture and bioinformatics analyses, we performed 
exome sequencing on a single Hapmap sample (NA12762) that 
was previously published (17). We found more than 99% con-
cordance with the published data. We also used three different 
approaches for further validation.
First, we performed high-throughput, multiplex PCR in 
microdroplets (Raindance Technologies; ref 18) and sequencing 
to more than 100-fold coverage for 179 genes (SI Appendix, 
Table S5) in eight cases. More than 99% of the variants were 
identical (Fig. 2B; SI Appendix, Table S6). The 100-fold coverage 
did not result in a substantial increase in variant discovery, 
conﬁrming our estimates that our coverage of the exome was 
adequate for the identiﬁcation of variants in most instances.
Second, we genotyped 43 of these cases using an Illumina SNP 
array comprising more than 733,000 probes. We found excellent 
concordance (94.2%) between the microarray calls and the 
exome sequencing analysis in that sample (Fig. 2B and Dataset 
S2). Finally, we performed PCR ampliﬁcation and Sanger se-
quencing for 25 variants corresponding to 24 genes in 50 cases. 
Again, we found excellent concordance (93.5%) of the exome 
capture calls with the calls generated by conventional Sanger 
sequencing (SI Appendix, Fig. S2). Taken together, these results 
indicate that our methods for exome-enrichment, sequencing, 
and bioinformatic analysis produce robust results.
Identiﬁcation of Protein Coding Sequence Variation in DLBCL. The
mutational patterns of these 322 DLBCL cancer genes in the 73
primary lymphomas, as well as 21 cell lines, are depicted in Fig.
3A. The median number of DLBCL cancer gene alterations per
patient was 16 (mean, 17).
Fig. 3B shows the frequency of the DLBCL cancer genes, which
followed a classic long tail distribution. Our data identify a num-
ber of known cancer-related genes in DLBCL that have been
previously reported and include TP53 (23), MYD88 (24), PIM1
(25), CARD11 (13), and BCL6 (25). Our data also implicate
a number of cancer-related genes that were not previously linked
to DLBCL, including PIK3R1, ARID1A, MTOR, and IDH1.
These data indicate that the spectrum of mutations and genes
involved in lymphomas, and potentially other cancers, may be
much larger than has been previously appreciated.
Gene Expression–Based Subgroups of DLBCL Demonstrate Distinct
Mutation Patterns. To better understand potential subgroup-
related differences in observed patterns of DLBCL mutations, we
performed gene expression proﬁling using Affymetrix microarrays
to distinguish activated B cell-like DLBCLs (n = 29) and germinal
center B cell-like DLBCLs (n = 35). We found 12 genes (Fig. 3C)
with a frequency of at least 10% in each subgroup that were
differentially mutated between the two groups (P < 0.05, Fisher’s
exact test). Genes that were more frequently mutated in ABC
DLBCLs included MYD88, KLHL14, CD79B, and SIGLEC10,
whereas GNA13, BCL2, and EZH2 were more frequently
mutated in GCB DLBCL. Of these, we also found GNA13 and
EZH2 to be recurrently mutated in Burkitt lymphoma (26),
another tumor derived from germinal center B cells.
J
B
I
Sequenced Cases
C
0%
10%
20%
30%
40%
50%
0 3 6 9
0%
10%
20%
30%
40%
50%
0 3 6 9
All DLBCL Indels
Number of Nucleotides
inserted or deleted
Proportion
of 
Indels
DLBCL Cancer Gene Indels
Number of Nucleotides
inserted or deleted
All DLBCL 
Exome Variants
DLBCL Cancer Gene 
Exome Variants
F G
Missense
Nonsense
Frameshift
Synonymous G      A 
C       T
0%
10%
20%
30%
40%
50%
A      G
T      C
G      T
C      A
C      G
G      C
T      A
A      T
T      G
A      C
Transition
TransversionProportionof base
alterations
P<10-6
Proportion
of 
Indels
80%
100%
60%
20%
40%
0
Multiplex PCR
and Sequencing
(Raindance)
N=8
SNP Arrays, N=43
Concordance
with 
Exome 
Sequencing
A
0
20
40
60
80
100
Average
Exome
Coverage
Targeted Coverage: (30X)
D E
C
u
m
u
la
ti
ve
 D
LB
C
L 
Ex
o
m
e
V
ar
ia
n
ts
 Id
en
ti
fie
d
Discovery Set
(N=34)
Prevalence Set
(N=39)
0%
20%
40%
60%
80%
100%
0 20 40 60
Number of Primary Cases
20000
30000
0
10000
C
u
m
u
la
ti
ve
 D
LB
C
L 
Ex
o
m
e
Ra
re
 V
ar
ia
n
ts
 Id
en
ti
fie
d
Number of Cases
20 25 30
2000
3000
4000
5000
6000
5 10 15
0
1000
0C
u
m
u
la
ti
ve
 D
LB
C
L 
Ex
o
m
e
A
cq
u
ir
ed
 V
ar
ia
n
ts
 Id
en
ti
fie
d
H
Cell Lines
(N=21)
Fig. 2. Exome sequencing in DLBCLs. (A) Bar graph depicts
the coverage achieved in each of the cases. The black line
indicates our targeted level of 30-fold coverage. (B) Bar
graph depicts the overlap between the variants identiﬁed
by exome sequencing and multiplex PCR followed by deep
sequencing (Raindance) in 179 genes in eight cases, as well
as exome sequencing and SNP arrays in 43 cases. (C) Plot
indicates the average number of additional sequence var-
iants detected in the exomes as a function of adding each
additional case. (D) Plot indicates the cumulative estimated
number of rare exome variants discovered as a function of
sample size. (E) Plot indicates the cumulative estimated
number of somatically acquired exome variants discovered
as a function of sample size (n = 1 through n = 34). (F) Pie
chart indicates the relative distribution of missense, non-
sense, frameshift, and synonymous base alterations in the
entire dataset. (G) Pie chart indicates the relative distribu-
tion of missense, nonsense, frameshift, and synonymous
base alterations in the 322 DLBCL cancer genes. (H) Histo-
gram shows the relative distribution of different mutation
classes in the 322 DLBCL cancer genes. The difference be-
tween the rates of transitions and transversions was highly
statistically signiﬁcant (P < 10−6). (I) Plot shows the relative
sizes of all insertions/deletions in the entire dataset. (J) Plot
shows the relative sizes of all insertions/deletions among
the 322 DLBCL cancer gene variants.
(16). We eliminated common genetic variants that occurred in our 
set of normal controls identiﬁed from dbSNP (19), the 1,000 
genomes project (17), and 256 recently published exomes from 
otherwise healthy individuals (20–22).
Our methods for identifying candidate DLBCL cancer genes 
are detailed in the SI Appendix. We developed a statistical model 
for comparing the characteristics of the somatically mutated 
genes in our discovery set of 34 tumor-normal pairs to previously 
validated cancer genes. We modeled several variables including 
frequency of nonsynonymous variation in the gene, frequency of 
somatic mutation, gene size, rate of nonsynonymous variation in 
healthy controls, and the predicted effect of the genetic alter-
ation on the encoded protein. DLBCL cancer genes were iden-
tiﬁed as those that had a score distribution most similar to those 
of the previously validated cancer genes (P < 10−6).
We identiﬁed 322 candidate DLBCL cancer genes as recurrently 
somatically mutated in DLBCL (Dataset S3). The majority of the 
52 known cancer-related genes and the remaining 270 genes have 
not been previously identiﬁed as having a role in lymphomas. 
Among these 322 DLBCL cancer genes, we identiﬁed a total of 
1,418 variants in these cases (Fig. 2G; Dataset S4). There was a 
higher proportion of each category of nonsynonymous mutations 
including missense (66.4%), nonsense (2.4%), and frameshift 
(2.5%), and fewer synonymous mutations (28.7%) in these genes 
compared with the patterns observed in the entire exome.
Once again, we observed a predominance of transitions (P < 
10−6, χ2 test; Fig. 2H). Overall, the sizes of the insertions and
deletions in these DLBCLs preserved reading frames, with peaks 
observed at insertion/deletion sizes of three, six, nine, and so on 
(Fig. 2I). However, in the 322 DLBCL cancer genes, we noted 
a signiﬁcant depletion of indel sizes that were multiples of three 
(Fig. 2J; P < 0.01, χ2 test).
Determination of Genes Enriched with AICDA-Related Mutations.We
further examined the potential role of AICDA (AID) in the ac-
quisition of these somatic mutations in our DLBCL cases. For the
322 DLBCL cancer genes, we determined the number of ac-
quired mutations where the reference sequence was “C,” and of
those, the fraction that fell into WRCY motifs (and the reverse
complement), which are associated with AICDA activity (29).
We performed a Fisher’s exact test to determine the signiﬁ-
cance of enrichment for mutations in the WRCY motifs com-
pared with the background rate.We found signiﬁcant enrichment
(P < 0.05) of WRCY motifs in PIM1, BTG1, and CD79B, sug-
gesting that AICDA is a signiﬁcant contributor to the somatic
alterations in these genes.
Gene alterations in PIM1, BTG1, and CD79A have not been
described in most solid tumors, suggesting AICDA-related alter-
ations are a lymphoma-speciﬁc mechanism, similar to their de-
scribed role in B-cell biology.
PIK3CD Is Identiﬁed as an Oncogene, and PI3 Kinase Inhibition Is a
Potential Therapeutic Approach in DLBCL. Deregulation of the PI3
kinase pathway is a common feature of many cancers (30). We ob-
served three separate cases withmutations in thePIK3CD gene, which
is not thought to be an oncogene. A single point mutation T → G
(Fig. 4A), conﬁrmed by Sanger sequencing (Fig. 4B), was identi-
ﬁed in the catalytic domain of the PIK3CD gene, which altered the
encoded amino acid from one with an uncharged side chain (as-
paragine) to one with a positively charged side chain (lysine).
We found mutations in two additional known oncogenes in the
PI3 kinase pathway, PIK3R1 and MTOR, pointing to deregulation
of the PI3 kinase pathway as an important oncogenic mecha-
nism in DLBCLs. Other key members of the pathway with
known oncogenic roles, including PTEN, FOXO3, and GSK3,
were not mutated in our cases. Similar to patterns observed
previously in PIK3CA (30), the mutations in PIK3CD, PIK3R1,
and MTOR appear to spread across multiple locations of the
gene (Fig. 4C) rather than clustering in a single hotspot.
We modeled the PIK3CD protein structure based on that of its
paralog PIK3CG, which has been determined through crystallog-
raphy (31). The identiﬁed mutation lies in the catalytic domain in
the predicted structure of the protein (Fig. 4D). We overexpressed
the WT and the mutant PIK3CD constructs in the FL5.12 lym-
phoma cell line that is well characterized for its IL3-dependent PI3
kinase signaling (32). In these cells, withdrawal of IL3 is associated
with a measurable decrease in PI3 kinase signaling and decreased
phophorylated AKT, which is directly downstream of PI3 kinase
and provides proliferative signals. In cells expressing the WT form
of PIK3CD, we found that withdrawal of IL3 was associated with
a measurable decrease in phosphorylated AKT S473 (Fig. 4E).
There was no measurable decrease in the phosphorylated AKT in
cells expressing the mutant form of PIK3CD, suggesting that the
mutation had an activating effect (Fig. 4E). These observations
were conﬁrmed in three experimental replicates, all of which
showed that IL3 withdrawal was associated with signiﬁcant down-
regulation in phosphorylated AKT in cells expressingWT PIK3CD
(P = 0.04), but not in cells expressing mutant PIK3CD (P = 0.44;
Fig. 4F). ELISA experiments also demonstrated similar patterns of
PI3 kinase activation in cells expressing mutant PIK3CD (SI Ap-
pendix, Fig. S8).
Among PIK3CD, PIK3R1, and MTOR, only MTOR was found
to be mutated in multiple cell lines (in addition to patient cases).
We investigated the effects of a small molecule inhibitor of PI3
kinase, BKM120 (Novartis), on the viability of 21 DLBCL cell
lines (Fig. 4G). The three cell lines with MTOR mutations had,
on average, a ﬁvefold higher sensitivity to PI3 kinase inhibition
than those 18 cell lines that did not harbor these mutations
(P = 0.005, Wilcoxon rank test). These results strongly suggest
that the presence of mutations in MTOR is associated with
sensitivity to PI3 kinase inhibition.
Comparison with Other Genetic Studies Reveals the Striking Genetic
Heterogeneity of DLBCL. Shortly after the completion of our study
in June 2011, and during revisions, three separate studies ex-
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The spans of the arcs indicate the relative numbers of different genes an-
notated with respect to gene ontology (37) terms. Representative genes in 
each group are shown next to each arc. Terms that match the described 
hallmarks of cancer (27) are marked with an asterisk.
Functional Categorization of Recurrently Mutated Genes in DLBCL. 
Twelve gene ontologies accounted for more than half of the 
DLBCL cancer genes (n = 203; Fig. 3D). Biological processes 
comprising signal transduction (e.g., PIK3CD, PDGFRA) and 
chromatin modiﬁcation (e.g., MLL3, SETD2) were most com-
monly implicated as DLBCL cancer genes (SI Appendix, Fig. S3). 
A number of these biological processes have been directly im-
plicated as hallmarks and enabling characteristics of cancer (27). 
Thus, a number of these DLBCL cancer genes have directly dis-
cernible roles that impact the growth and development of tumors.
The role of signal transduction pathways in tumors is of par-
ticular interest because they may be therapeutic targets for small 
molecule inhibitors. Signaling pathways (28) including JAK-
STAT, ubiquitin, WNT, NF-KB, Notch, and PI3 kinase signaling 
were recurrently mutated in DLBCLs, although mutations in 
each signaling pathway occurred in only a minority of these 
cases. Many of these pathways have not been conclusively im-
plicated in lymphomas and might be potential therapeutic targets 
in DLBCL subsets deﬁned by mutations in them, a notion that 
we further explored experimentally.
arise from the inherent genetic heterogeneity of the DLBCL
tumors, an effect that we also observed in other cancers (SI
Appendix, Fig. S7).
Discussion
Through whole-genome sequencing and whole-exome sequenc-
ing, we identiﬁed the spectrum of sequence variation that occurs
in DLBCL. Our data suggest that the majority of genetic variants
in DLBCL are stochastically acquired. In all, we identiﬁed a total
of 322 candidate DLBCL cancer genes that have recurrent so-
matic mutations in patients with DLBCL. We identiﬁed a role
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Fig. 4. PI3 kinase pathway in DLBCLs. (A) Deep sequencing
reads identify a somatic mutation in PIK3CD in a DLBCL tu-
mor. Sequencing reads matching the genome perfectly are
shown in gray. The two samples differ only in a single nu-
cleotide that is G in the tumor, but T (i.e., identical to ref-
erence genome) in the matched normal. The data were
displayed using the Integrated Genomics Viewer (38). (B)
Chromatograms display the results from Sanger sequencing
in the same case. The sequenced bases demonstrate a T→G
alteration in the tumor but not the matched normal. (C)
Distribution of mutations occurring in the PI3 kinase path-
way–related genes: PIK3R1, PIK3CD, and MTOR. Each blue
diamond marks an individual mutation. Eleven separate
events occurred in these three genes. (D) A molecular model
of PIK3CD based on threading through the PIK3CG crystal
structure. The location of the Asn-972 Lys (N972K) mutation
identiﬁed in our sequencing data is highlighted within the
C-lobe of the catalytic domain. (E) Western blot depicts the
alteration in phosphorylated AKT expression initially and
3 h after the withdrawal of IL3. The relative expression of
phospho-AKT (S473), with total AKT and β-actin loading
controls, are shown. (F) The relative change in PI3 kinase
activity is depicted as a function of altered phospho-AKT
protein expression normalized to β-actin expression in three
separate experiments. The P values were computed using
a Student t test comparing the altered PI3 kinase activity in
the cells before and after IL3 withdrawal. (+, IL3 exposure; −,
IL3 withdrawal). (G) IC50s for 21 cell lines treated with a PI3
kinase inhibitor are shown. The three cell lines with mutated
MTOR have approximately ﬁvefold lower IC50s than the 18
cell lines with WT MTOR (P = 0.005).
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Fig. 5. Overlaps in genes discovered in multiple cancer studies. The Venn
diagrams depict the comparison of gene mutations from the four DLBCL
studies. The number in parentheses indicates the number of genes identiﬁed
in each study. The gene lists were as follows: Morin et al. (Table S1 in Ref. 7,
genes with conﬁrmed somatic cases), Lohr et al. (Table 1 in Ref. 33, top 58
genes), and Pasqualucci et al. (Table S3 and Fig. 4 in Ref. 8, validated somatic
genes).
ploring the genetics of DLBCL using similar methodologies and 
deep sequencing were published (7, 8, 33). Multiple studies ap-
plying these methodologies in the same cancer type have gen-
erally been lacking thus far, and these publications provided 
an unusual opportunity for testing the overlapping mutations 
identiﬁed by the different studies.
We constructed Venn diagrams depicting the overlap between 
genes identiﬁed in the three studies and our study as shown in 
Fig. 5. We initially assumed that our study comprising 73 primary 
DLBCL cases would be sufﬁcient to identify the vast majority of 
recurrent genetic alterations in the disease. Surprisingly, we 
noted relatively modest overlaps of roughly 10–20% among the 
four different studies. Even genes that overlapped between dif-
ferent studies often varied. Similar patterns were observed when 
we simply compared the overlap between all somatically mutated 
genes in these studies. The overlap of more frequently mutated 
genes was still incomplete; when we limited the analysis to those 
17 genes that were mutated in more than 10% of the cases 
reported by Lohr et al. (33), the overlap between the different 
studies including ours approached 70% (SI Appendix, Fig. S6). 
Even in that scenario, different studies had overlap with different 
genes. The remaining 30% of the genes mutated in at least 10%
of the cases in that study were not detected by any of the 
remaining three studies. The overlap is still lower for genes with 
fewer mutation events. These observations suggest that there is 
considerable genetic heterogeneity in the disease that contrib-
utes the observed patterns of disparate mutations.
Although genes that do not overlap among studies might 
signify some false positives, our analysis indicates that a number 
of validated oncogenes and tumor suppressor genes were 
identiﬁed in just one study. Examples include NOTCH1 (34), 
CD74 (34), BCL10, IRF4, MALT1, TET2 (7), BCR, ETV6 
(33), PIK3R1, MTOR, KIT, PDGFRA, and ARID1A (our 
study). The number of identiﬁed cancer genes appeared to in-
crease linearly as a function of the size of the study, further 
indicating that the differences between the individual studies
for a number of known and previously unknown oncogenes.
Many of these genes, including ARID1A, KIT, and IDH1, have
not been previously implicated in DLBCL by any previous study.
A central observation of our study is the striking genetic het-
erogeneity that underlies a relatively common cancer. As we
demonstrated, there is a relatively low overlap between four dif-
ferent studies that explore the genetics of DLBCL. Although dif-
ferences in methodology, the diversity of patient populations, and
number of patients might contribute to this low overlap, our data
indicate that the major driver of the low overlap is the inherent
genetic heterogeneity of the disease. Consistent with this observed
heterogeneity, we demonstrate that the number of rare variants
and somatic mutations increases linearly with the increased
number of cases, suggesting that continued sequencing of tumors
will implicate new variants and new cancer-related genes.
Gene expression proﬁling has previously revealed aspects of the
heterogeneity of the disease, particularly with regard to cell of or-
igin of DLBCLs (2). Our data indicate that recurrent mutations in
12 genes were clearly enriched between ABC DLBCLs and GCB
DLBCLs. Thus, the two DLBCL subgroups share the mutational
patterns of many more genes, suggesting that shared mechanisms
underlie their biology. The striking genetic heterogeneity observed
in the disease as a whole is also recapitulated in these subgroups.
The recognition of recurrent mutations in the gene coding
regions in the disease is an important early step toward un-
derstanding its biology and potential therapeutic possibilities. So-
matic mutations have previously been observed in multiple genes
in the NF-κB pathway, including TNFAIP3(A20) and CARD11
(35). Both of these genes were found to have somatic cases in our
study and at least one of the recently published DLBCL studies (7,
8, 33). Histone-modifying genes, such as MLL2 andMEF2B, were
found to be frequently mutated in DLBCL (32% and 11.4%, re-
spectively) (7). Although MLL2 was not included in our exome
capture library, which was designed using build 36 of the human
genome, we also observed somatic mutations in MEF2B and
CREBBP, an acetyltransferase gene reported previously (34).
MLL3, which forms complexes with MLL2, was the most
frequently mutated gene in our cases. Our data also implicate
AICDA-related mutations as a major mechanism underlying ge-
netic mutations in the genes PIM1, BTG1, and CD79B. These
observations highlight the diverse biological mechanisms un-
derlying the observed genetic diversity.
The genetic heterogeneity of DLBCLs and other cancers
implies that no matter what recurrently altered gene or pathway
is considered, only a minority of patients are likely to be affected.
For that subgroup of patients whose tumors harbor a growing
number of recognized genetic lesions that can be targeted ther-
apeutically, the recognition of such alterations can make a crucial
difference in their treatment. A number of genetic mutations
we identiﬁed, including those in PIK3CD, KIT, and PDGFRA,
suggest therapeutic possibilities in the affected patients. Our data
suggest that such targeted therapeutic approaches in patients will
need to be combined with carefully selected assays for those ge-
netic lesions to better understand their role in response to tar-
geted therapies. Our data also have major implications for how
we model cancers and the need to ascertain whether extant
mouse and other models recapitulate the primary disease. Thus,
our study sheds light on the genetic heterogeneity of lymphomas,
as well as cancers in general, and underscores the need for in-
dividualized approaches for treating patients.
Methods
Detailed methods are provided in the SI Appendix. Whole genome se-
quencing and exome sequencing were performed on the Illumina platform.
Sequencing reads were mapped to the reference genome, and variants were
identiﬁed, collated, and annotated.
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